RNAC Q4 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+636.9% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$13M-188.9% margin

Net Income

-$15M-223.7% margin

EPS (Diluted)

$-8.54

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$100M

Total Liabilities

$91M

Stockholders' Equity

$8M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$903,000	+636.9%
Gross Profit	$7M	$903,000	+636.9%
Operating Income	-$13M	-$14M	+13.3%
Net Income	-$15M	-$15M	-1.6%